Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $125,000.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Robert Hershberg sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total transaction of $125,000.00. Following the transaction, the director owned 162,156 shares in the company, valued at $810,780. The trade was a 13.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $4.36 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The company’s fifty day moving average price is $3.57 and its 200-day moving average price is $3.39. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $7.18. The firm has a market capitalization of $2.33 billion, a PE ratio of -4.19 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%. The firm had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. During the same quarter last year, the business earned ($0.41) EPS. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.94 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on RXRX. Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a report on Monday, August 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.06.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently made changes to their positions in RXRX. Norges Bank purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth $23,473,000. First Trust Advisors LP grew its position in shares of Recursion Pharmaceuticals by 15.2% in the first quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock valued at $8,015,000 after purchasing an additional 344,035 shares during the period. Bank of America Corp DE boosted its holdings in Recursion Pharmaceuticals by 18.2% in the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after buying an additional 384,486 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Recursion Pharmaceuticals during the 1st quarter worth $7,370,000. Finally, Bank of New York Mellon Corp raised its position in shares of Recursion Pharmaceuticals by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock valued at $4,490,000 after buying an additional 331,048 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.